50-04-4

  • Product Name:Cortisone acetate
  • Molecular Formula:C23H30O6
  • Purity:99%
  • Molecular Weight:402.488
InquiryAdd to cart

Product Details;

CasNo: 50-04-4

Molecular Formula: C23H30O6

Appearance: solid

Factory Supply High Purity Top Purity 99% Cortisone acetate 50-04-4 In Bulk Supply

  • Molecular Formula:C23H30O6
  • Molecular Weight:402.488
  • Appearance/Colour:solid 
  • Vapor Pressure:0mmHg at 25°C 
  • Melting Point:237-240 °C(lit.) 
  • Refractive Index:212 ° (C=1, MeOH) 
  • Boiling Point:567.8 °C at 760 mmHg 
  • PKA:12.32±0.60(Predicted) 
  • Flash Point:311.2 °C 
  • PSA:97.74000 
  • Density:1.28 g/cm3 
  • LogP:2.56060 

Cortisone acetate(Cas 50-04-4) Usage

Description

Cortisone acetate is a synthetic glucocorticoid with anti-inflammatory properties. It decreases the size of Bacillus Calmette-Guérin (BCG) vaccine-induced dermal lesions and tuberculin reactions in rabbits when administered at 2 mg/kg on alternate days over the course of 46 days. It also reduces the number and percentage of activated lesion-infiltrating mononuclear cells and decreases the amount of caseous necrosis and ulceration. Cortisone acetate (2.5 mg/kg per day, s.c.) slows tissue regeneration in a rabbit model of wound healing. It also decreases the number of dexamethasone binding sites on isolated human lymphocytes by 30%. Formulations containing cortisone acetate have been used to relieve inflammation, pruritic manifestations of corticosteroid-responsive dermatoses, and in the treatment of immune and allergic disorders.

Chemical Properties

solid

Originator

Cortone Acetate,MSD,US,1950

Uses

Cortisone Acetate (Hydrocortisone Acetate EP Impurity D) is a glucocorticoid. Cortisone Acetate is an antiinflammatory agent. Cortisone Acetate is bioavailable and readily converted to the therapeutically active form, Hydrocotisone (H714615).

Manufacturing Process

The following technique is described in US Patent 2,541,104. A solution of 2.0 g of 3(α)-hydroxy-21-acetoxy-11,20-diketo-pregnane, which can be prepared as described in Helv. Chim. Acta 27, 1287 (1944), is treated in a mixture of 25 cc of alcohol and 6.4 cc of acetic acid at 0°C with 6.0 g of potassiumcyanide. The solution is allowed to warm to room temperature and after 3 hours is diluted with water. The addition of a large volume of water to the alcohol-hydrogen cyanide mixture precipitates a gum which is extracted with chloroform or ethyl acetate. The extract is washed with water, and evaporated to small volume under reduced pressure. The crystalline precipitate (1.3 g) consists of 3(α),20-dihydroxy-20-cyano-21-acetoxy-11-keto-pregnane; dec. 175° to 185°C.A solution of 0.60 g of chromic acid in 1.2 cc of water and 11 cc of acetic acid is added to a solution containing about 1.2 g of 3(α),20-dihydroxy-20-cyano- 21-acetoxy-11-ketopregnane at room temperature. After 1 hour, water is added and the product, which precipitates, is filtered and recrystallized from ethyl acetate to produce 3,11-diketo-20-hydroxy-20-cyano-21-acetoxypregnane; dec. 214° to 217°C. 0.40 cc of phosphorus oxychloride is added to a solution containing about 950 mg of 3,11-diketo-20-hydroxy-20-cyano-21-acetoxy-pregnane dissolved in 3 cc of pyridine. After standing at room temperature for 24 hours, the solution is poured into water and dilute hydrochloric acid, extracted with benzene and concentrated to dryness. The crude product, after chromatography gives one main constituent, namely δ17-3,11-diketo-20-cyano-21-acetoxy-pregnene; MP 189° to 190°C. A solution of 1.0 g of δ17-3,11-diketo-20-cyano-21-acetoxy-pregnene in 10 cc of benzene is treated with 1.0 g of osmium tetroxide and 0.43 g of pyridine. After standing at room temperature for 18 hours, the resulting solution is treated successively with 50 cc of alcohol, and with 50 cc of water containing 2.5 g of sodium sulfite. The mixture is stirred for 30 hours, filtered, and the filtrate acidified with 0.5 cc of acetic acid and concentrated to small volume in vacuo. The aqueous suspension is then extracted four times with chloroform, the chloroform extracts are combined, washed with water and concentrated to dryness in vacuo. Recrystallization of the residue from acetone gives 9°C. This compound is then treated with acetic anhydride and pyridine for 15 minutes at room temperature to produce 3,11,20-triketo-17(α)-hydroxy-21-acetoxypregnane or cortisone acetate.

Therapeutic Function

Glucocorticoid

General Description

Cortisone acetate, 21-(acetyloxy)-17-hydroxypregn-4-ene-3,11,20-trione, is the 21-acetate of naturally occurring cortisone with good systemicanti-inflammatory activity and low-to-moderate salt-retentionactivity after its in vivo conversion to hydrocortisoneacetate. This conversion is mediated by 11β-hydroxysteroiddehydrogenase. It is used for the entire spectrum of uses discussedpreviously under the heading, “Therapeutic Uses ofAdrenal Cortex Hormones”—collagen diseases, Addisondisease, severe shock, allergic conditions, chronic lymphocyticleukemia, and many other indications. Cortisone acetateis relatively ineffective topically, mainly because itmust be reduced in vivo to hydrocortisone. Its plasma halflifeis only about 30 minutes, compared with 90 minutes to3 hours for hydrocortisone.

Purification Methods

Crystallise -1cortisone-21-acetate from acetone or CHCl3. The UV has 15,800 M-1cm at 238nm in dioxane. [Sarett J Biol Chem 162 601 1946, Beilstein 8 III 4058, 5 IV 3481.]

InChI:InChI=1/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21+,22+,23+/m1/s1

50-04-4 Relevant articles

Method for treating prednisone acetate mother liquor

-

Paragraph 0034-0066, (2021/06/02)

The invention relates to the technical f...

Bidentate Nitrogen-Ligated I(V) Reagents, Bi(N)-HVIs: Preparation, Stability, Structure, and Reactivity

Xiao, Xiao,Roth, Jessica M.,Greenwood, Nathaniel S.,Velopolcek, Maria K.,Aguirre, Jordan,Jalali, Mona,Ariafard, Alireza,Wengryniuk, Sarah E.

, p. 6566 - 6576 (2021/05/06)

Hypervalent iodine(V) reagents are a pow...

Preparation method of cortisone-21-acetate

-

Paragraph 0038; 0039; 0044-0048; 0053-0057; 0062-0066; 0071, (2020/11/25)

The invention provides a preparation met...

Preparation method of prednisone

-

Paragraph 0012; 0029-0030; 0033-0034; 0037-0038, (2021/03/05)

The invention discloses a preparation me...

50-04-4 Process route

anecortave
7753-60-8

anecortave

Cortisone acetate
50-04-4

Cortisone acetate

Conditions
Conditions Yield
anecortave; With tetrafluoroboric acid; In dichloromethane; acetone; at -5 - 0 ℃; for 5h; Inert atmosphere;
With Jones reagent; In dichloromethane; acetone; at 0 - 5 ℃; for 4h; Reagent/catalyst; Solvent; Temperature; Inert atmosphere;
95.8%
C<sub>23</sub>H<sub>29</sub>BrO<sub>6</sub>

C23H29BrO6

Cortisone acetate
50-04-4

Cortisone acetate

Conditions
Conditions Yield
With acetic acid; zinc; In dichloromethane; at 10 ℃; for 3h; Temperature;
79.5%

50-04-4 Upstream products

  • 50-03-3
    50-03-3

    hydrocortisone acetate

  • 1499-59-8
    1499-59-8

    21-acetoxy-17-hydroxy-5β-pregnane-3,11,20-trione

  • 988-16-9
    988-16-9

    21-acetoxy-3,3-ethanediyldioxy-17-hydroxy-pregn-5-ene-11,20-dione

  • 64-19-7
    64-19-7

    acetic acid

50-04-4 Downstream products

  • 53-06-5
    53-06-5

    Cortisone

  • 125-10-0
    125-10-0

    prednisone acetate

  • 28444-83-9
    28444-83-9

    4-Chlor-cortison-21-acetat

  • 3751-02-8
    3751-02-8

    21-acetoxy-17-hydroxy-5α-pregnane-3,11,20-trione

Shopping Cart

Clear Inquiry